199 related articles for article (PubMed ID: 34083030)
1. Oral Anticoagulation Therapy for Venous Thromboembolism in Norway: Time Trends and Treatment Patterns.
Ghanima W; Schultze A; Donaldson R; Brodin E; Halvorsen S; Graham S; Carroll R; Ulvestad M; Lambrelli D
Clin Ther; 2021 Jul; 43(7):1179-1190.e3. PubMed ID: 34083030
[TBL] [Abstract][Full Text] [Related]
2. Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017.
Lutsey PL; Walker RF; MacLehose RF; Alonso A; Adam TJ; Zakai NA
Res Pract Thromb Haemost; 2019 Oct; 3(4):668-673. PubMed ID: 31624786
[TBL] [Abstract][Full Text] [Related]
3. Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment-A nationwide register-based study.
Glise Sandblad K; Schulman S; Rosengren A; Sörbo J; Philipson J; Hansson PO
J Intern Med; 2023 Dec; 294(6):743-760. PubMed ID: 37641391
[TBL] [Abstract][Full Text] [Related]
4. Post-Discharge Treatment Patterns among Patients Treated with Apixaban or Warfarin during Hospitalization for Venous Thromboembolism (VTE).
Coons JC; Anupindi VR; Doshi R; DeKoven M; Dai F; Russ C; Stellhorn R; Cheng D; Shi L; Deeba S; Hines DM
J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38930040
[No Abstract] [Full Text] [Related]
5. Venous thrombosis recurrence risk according to warfarin versus direct oral anticoagulants for the secondary prevention of venous thrombosis.
Zakai NA; Walker RF; MacLehose RF; Koh I; Alonso A; Lutsey PL
Res Pract Thromb Haemost; 2021 Aug; 5(6):e12575. PubMed ID: 34430789
[TBL] [Abstract][Full Text] [Related]
6. Payer approval and rejection of oral anticoagulant prescriptions and prescription abandonment patterns among patients with venous thromboembolism.
Hines DM; Doshi R; Anupindi VR; Dai F; Russ C; Stellhorn R; Cheng D; Deeba S; Wang Y; DeKoven M
J Manag Care Spec Pharm; 2024 May; 30(5):441-455. PubMed ID: 38277234
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival in venous thromboembolic disease: rivaroxaban vs. warfarin - propensity score matching study.
Ramos-Isaza E; Tuta-Quintero E; Bastidas-Goyes A; Diaz-Quijano D; Aponte-Murcia C; Espitia-Angel J; Pinto-Beltran D; Rincón-Hernández J; Sánchez-Cuellar J; Pérez-Bueno J; Giraldo-Cadavid LF
BMC Pharmacol Toxicol; 2023 Dec; 24(1):77. PubMed ID: 38093310
[TBL] [Abstract][Full Text] [Related]
8. Dynamic Patterns and Persistence of Anticoagulation Therapy in Patients with Venous Thromboembolism in South Korea: A Nationwide Cohort Study.
Yoon D; Jeong HE; Choi S; Shin JY; Bang SM
Thromb Haemost; 2024 Feb; 124(2):152-162. PubMed ID: 37285903
[TBL] [Abstract][Full Text] [Related]
9. Equivalent thrombotic risk with Warfarin, Dabigatran, or Enoxaparin after failure of initial direct oral anticoagulation (DOAC) therapy.
Shyu M; Liu A; Srikureja A; Gregorian A; Srisuwananukorn A; Tremblay D; Naymagon L
J Thromb Thrombolysis; 2024 Apr; ():. PubMed ID: 38643437
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life associated with warfarin and direct oral anticoagulants in venous thromboembolism.
Fang MC; Go AS; Prasad PA; Zhou HX; Parks AL; Fan D; Portugal C; Sung SH; Reynolds K
Thromb Res; 2022 Aug; 216():97-102. PubMed ID: 35779378
[TBL] [Abstract][Full Text] [Related]
11. Adherence and persistence to direct factor Xa inhibitors in the community following newly diagnosed venous thromboembolism: a retrospective pharmacy-linkage study.
Dix C; Bortz H; da Gama M; Treloar M; Reynolds M; Ramanan R; Day T; Tran H
Int J Pharm Pract; 2023 Sep; 31(5):528-533. PubMed ID: 37494677
[TBL] [Abstract][Full Text] [Related]
12. Trends in Oral Anticoagulant Use and Individual Expenditures Across the United States from 2014 to 2020.
Alkhezi OS; Buckley LF; Fanikos J
Am J Cardiovasc Drugs; 2024 May; 24(3):433-444. PubMed ID: 38583107
[TBL] [Abstract][Full Text] [Related]
13. Prevention of venous thromboembolism in ambulatory patients with cancer.
Khorana AA; Cohen AT; Carrier M; Meyer G; Pabinger I; Kavan P; Wells P
ESMO Open; 2020 Nov; 5(6):e000948. PubMed ID: 33229505
[TBL] [Abstract][Full Text] [Related]
14. Direct Oral Anticoagulants vs. Conventional Anticoagulants for the Treatment of VTE.
Yancey JR; Herman CJ
Am Fam Physician; 2024 Mar; 109(3):210. PubMed ID: 38574209
[No Abstract] [Full Text] [Related]
15. A retrospective assessment of venous recanalization outcomes for oral anticoagulant treatment in deep vein thrombosis.
Guzel A; Canbaz S
Vascular; 2024 Feb; ():17085381241236931. PubMed ID: 38409653
[TBL] [Abstract][Full Text] [Related]
16. Primary Care Clinicians' Prescribing Patterns of Reduced-Dose Direct Oral Anticoagulants for Extended-Phase Venous Thromboembolism Treatment.
Groat D; Martin KA; Rosovsky RP; Sanfilippo KM; Gaddh M; Baumann Kreuziger L; Federici E; Woller SC;
J Clin Med; 2023 Dec; 13(1):. PubMed ID: 38202103
[TBL] [Abstract][Full Text] [Related]
17. Proteomic analysis of extracellular vesicle cargoes mirror the cardioprotective effects of rivaroxaban in patients with venous thromboembolism.
Weiss L; Uhrig W; Kelliher S; Szklanna PB; Prendiville T; Comer SP; Edebiri O; Egan K; Lennon Á; Kevane B; Murphy S; Ní Áinle F; Maguire PB
Proteomics Clin Appl; 2024 Jan; ():e2300014. PubMed ID: 38193270
[TBL] [Abstract][Full Text] [Related]
18. Health Literacy and Treatment Satisfaction Among Patients with Venous Thromboembolism.
Mefford MT; Zhou H; Fan D; Fang MC; Prasad PA; Go AS; Portugal C; Chang JM; Reynolds K
J Gen Intern Med; 2023 May; 38(7):1585-1592. PubMed ID: 36326991
[TBL] [Abstract][Full Text] [Related]
19. Unapproved Dose of Direct Oral Anticoagulants for Venous Thromboembolism - Right or Wrong?
Adachi S; Adachi T; Nakano Y
Circ J; 2024 Feb; 88(3):380-381. PubMed ID: 38296552
[No Abstract] [Full Text] [Related]
20. Patterns and Persistence of Anticoagulant Use in the Treatment of Venous Thromboembolism: Insights from South Korea.
Germini F; Chan NC
Thromb Haemost; 2024 Feb; 124(2):163-165. PubMed ID: 37463605
[No Abstract] [Full Text] [Related]
[Next] [New Search]
